Explore

Trendline Trendline
PharmaLogic and Ratio Therapeutics Expand Manufacturing Collaboration for Cancer Treatment

PharmaLogic and Ratio Therapeutics Expand Manufacturing Collaboration for Cancer Treatment

PharmaLogic and Ratio Therapeutics Expand Manufacturing Collaboration for Cancer Treatment
Trendline Trendline
Ratio Therapeutics and PharmaLogic Expand Collaboration for Radiopharmaceutical Development

Ratio Therapeutics and PharmaLogic Expand Collaboration for Radiopharmaceutical Development

Ratio Therapeutics and PharmaLogic Expand Collaboration for Radiopharmaceutical Development
Trendline Trendline
Molecular Targeting Technologies Unveils Promising Data for GEP-NET Cancer Treatment

Molecular Targeting Technologies Unveils Promising Data for GEP-NET Cancer Treatment

Molecular Targeting Technologies Unveils Promising Data for GEP-NET Cancer Treatment
Trendline Trendline
PanTher Therapeutics Advances Pancreatic Cancer Treatment with PTM-101, Appoints New Board Member

PanTher Therapeutics Advances Pancreatic Cancer Treatment with PTM-101, Appoints New Board Member

PanTher Therapeutics Advances Pancreatic Cancer Treatment with PTM-101, Appoints New Board Member
Trendline Trendline
InduPro Therapeutics Appoints Dr. Amanda J. Redig as Chief Medical Officer to Advance Oncology Programs

InduPro Therapeutics Appoints Dr. Amanda J. Redig as Chief Medical Officer to Advance Oncology Programs

InduPro Therapeutics Appoints Dr. Amanda J. Redig as Chief Medical Officer to Advance Oncology Programs
Trendline Trendline
Solu Therapeutics Receives FDA Fast Track Designation for STX-0712 in Leukemia Treatment

Solu Therapeutics Receives FDA Fast Track Designation for STX-0712 in Leukemia Treatment

Solu Therapeutics Receives FDA Fast Track Designation for STX-0712 in Leukemia Treatment
Trendline Trendline
Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment

Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment

Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment
Trendline Trendline
Ankyra Therapeutics Presents Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics Presents Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics Presents Novel IL-12 Anchored Immunotherapy at ASCO 2026
Trendline Trendline
Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors

Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors

Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors
Trendline Trendline
Ori Biotech and ImmuXell Partner to Advance TCR-T Cell Therapy for Cancer Treatment

Ori Biotech and ImmuXell Partner to Advance TCR-T Cell Therapy for Cancer Treatment

Ori Biotech and ImmuXell Partner to Advance TCR-T Cell Therapy for Cancer Treatment
Trendline Trendline
Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026
Trendline Trendline
Forlong Completes Phase I Trials of FL115 for Advanced Solid Tumors with Promising Results

Forlong Completes Phase I Trials of FL115 for Advanced Solid Tumors with Promising Results

Forlong Completes Phase I Trials of FL115 for Advanced Solid Tumors with Promising Results